Mitazalimab (ADC-1013, JNJ-64457107) is FcgammaR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment[1][2].
Molecular Weight:
(143.44 kDa)
Purity:
99.23
CAS Number:
[2055640-86-1]
Target:
TNF Receptor
Application Notes:
Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
